Daily Antiplatelets Other Than Aspirin Reduce Liver Cancer Risk but Increase Intracranial Hemorrhage Risk in Cirrhotic Patients

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2024 Oct 22

PMID 39435412

Authors

Chern-Horng Lee

Cheng-Li Lin

Tzung-Hai Yen

Sen-Yung Hsieh

Affiliations

Soon will be listed here.

Abstract

Purpose: Aspirin, known to reduce the risk of liver cancer, has been proposed as a preventive measure for patients with chronic hepatitis and cirrhosis. However, concerns regarding aspirin's potential to cause gastrointestinal (GI) mucosal injury and bleeding have emerged. Several antiplatelets other than aspirin (APOA) that pose a smaller risk of GI bleeding than aspirin have been proposed as potential aspirin substitutes. This study investigated whether APOAs were effective at reducing the risk of hepatocellular carcinoma (HCC). Additionally, we evaluated the safety of APOAs, specifically regarding their potential to increase the risk of GI bleeding, in a nationwide cirrhosis cohort.

Patients And Methods: For the period January 1, 2000, to December 31, 2017, we identified 686 993 patients with cirrhosis from a national database. A control group was established using 1:2 propensity score matching on the basis of sex, age, comorbidities, and medication use.

Results: Daily use of APOAs was significantly associated with lower incidences of HCC (aHR 0.67; 95% CI, 0.60-0.73; P < 0.001) and showed no significant increase in GI bleeding risk (aHR 1.04; 95% CI, 0.93-1.15; P = 0.533) compared to nonuse of APOAs. However, the risks of intracranial hemorrhage (aHR, 1.41; 95% CI, 1.18 to 1.69; < 0.001) and overall mortality (aHR, 2.03; 95% CI, 1.95 to 2.10; < 0.001) were higher in the APOA user group.

Conclusion: Our results suggest that although daily use of APOAs other than aspirin may decrease the HCC risk of patients with cirrhosis, it may also increase their risks of intracranial hemorrhage and overall mortality. Therefore, the use of APOAs as an alternative to aspirin for HCC prevention in patients with cirrhosis requires careful consideration.

References

Lee C, Shen C, Yen C, Yen T, Hsieh S . Discontinuing Hepatitis Activity Reduced Hepatocellular Carcinoma Recurrence after Primary Curative Therapy. J Pers Med. 2023; 13(3). PMC: 10052208. DOI: 10.3390/jpm13030397. View

Roquer J, Campello A, Gomis M, Ois A, Puente V, Munteis E . Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. J Neurol. 2005; 252(4):412-6. DOI: 10.1007/s00415-005-0659-5. View

Pang Q, Jin H, Qu K, Man Z, Wang Y, Yang S . The effects of nonsteroidal anti-inflammatory drugs in the incident and recurrent risk of hepatocellular carcinoma: a meta-analysis. Onco Targets Ther. 2017; 10:4645-4656. PMC: 5614766. DOI: 10.2147/OTT.S143154. View

Sacco M, Ribaldone D, Saracco G . Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?. Viruses. 2023; 15(12). PMC: 10748230. DOI: 10.3390/v15122451. View

Lee T, Hsu Y, Tseng H, Yu S, Lin J, Wu M . Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. JAMA Intern Med. 2019; 179(5):633-640. PMC: 6503573. DOI: 10.1001/jamainternmed.2018.8342. View

Tsai P, Kuo H, Hung C, Tseng K, Lai H, Peng C . Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J Hepatol. 2022; 78(2):281-292. DOI: 10.1016/j.jhep.2022.09.019. View

Pavlovic N, Kopsida M, Gerwins P, Heindryckx F . Activated platelets contribute to the progression of hepatocellular carcinoma by altering the tumor environment. Life Sci. 2021; 277:119612. DOI: 10.1016/j.lfs.2021.119612. View

Teo K, Lau G, Mak R, Leung H, Chang R, Tse M . Antiplatelet Resumption after Antiplatelet-Related Intracerebral Hemorrhage: A Retrospective Hospital-Based Study. World Neurosurg. 2017; 106:85-91. DOI: 10.1016/j.wneu.2017.06.015. View

Young S, Chau G, Lee I, Yeh Y, Chao Y, Huo T . Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. J Formos Med Assoc. 2019; 119(1 Pt 2):218-229. DOI: 10.1016/j.jfma.2019.04.018. View

10.

Pawitan Y, Yin L, Setiawan A, Auer G, Smedby K, Czene K . Distinct effects of anti-inflammatory and anti-thrombotic drugs on cancer characteristics at diagnosis. Eur J Cancer. 2015; 51(6):751-7. DOI: 10.1016/j.ejca.2015.02.004. View

11.

Hoshino H, Toyoda K, Omae K, Ishida N, Uchiyama S, Kimura K . Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial. Stroke. 2021; 52(11):3430-3439. PMC: 8547582. DOI: 10.1161/STROKEAHA.121.034378. View

12.

Zhang R, Guo H, Xu J, Li B, Liu Y, Cheng C . Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding. Oncotarget. 2016; 7(37):60609-60622. PMC: 5312405. DOI: 10.18632/oncotarget.11300. View

13.

Liu Y, Ren T, Xu X, Jin J . Association of aspirin and nonaspirin NSAIDs therapy with the incidence risk of hepatocellular carcinoma: a systematic review and meta-analysis on cohort studies. Eur J Cancer Prev. 2021; 31(1):35-43. DOI: 10.1097/CEJ.0000000000000663. View

14.

Pavlovic N, Rani B, Gerwins P, Heindryckx F . Platelets as Key Factors in Hepatocellular Carcinoma. Cancers (Basel). 2019; 11(7). PMC: 6678690. DOI: 10.3390/cancers11071022. View

15.

Gao C . Molecular pathological epidemiology in diabetes mellitus and risk of hepatocellular carcinoma. World J Hepatol. 2016; 8(27):1119-1127. PMC: 5037325. DOI: 10.4254/wjh.v8.i27.1119. View

16.

Braun A, Anders H, Gudermann T, Mammadova-Bach E . Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues. Front Oncol. 2021; 11:665534. PMC: 8311658. DOI: 10.3389/fonc.2021.665534. View

17.

Okazaki I, Maruyama K, Funatsu K, Kashiwazaki K, Tsuchiya M . Ten year survival rate of 131 patients with liver cirrhosis excluded the association of liver carcinoma at the establishment of diagnosis. Gastroenterol Jpn. 1980; 15(4):350-4. DOI: 10.1007/BF02774306. View

18.

Kishino T, Oyama T, Hotta K, Ishii E, Momoi T, Shimizu T . Risk of colonoscopic post-polypectomy bleeding in patients after the discontinuation of antithrombotic therapy. Turk J Gastroenterol. 2020; 31(11):752-759. PMC: 7759232. DOI: 10.5152/tjg.2020.19428. View

19.

Reiss A, Grossfeld D, Kasselman L, Renna H, Vernice N, Drewes W . Adenosine and the Cardiovascular System. Am J Cardiovasc Drugs. 2019; 19(5):449-464. PMC: 6773474. DOI: 10.1007/s40256-019-00345-5. View

20.

Yuhara H, Corley D, Nakahara F, Nakajima T, Koike J, Igarashi M . Aspirin and non-aspirin NSAIDs increase risk of colonic diverticular bleeding: a systematic review and meta-analysis. J Gastroenterol. 2013; 49(6):992-1000. DOI: 10.1007/s00535-013-0905-z. View